Severe hypoglycaemia [defined as symptomatic hypoglycaemia requiring third-party assistance with a blood glucose level of <2.0 mmol/L (<36 mg/dL) or recovery after oral carbohydrate, intravenous glucose, or glucagon administration] occurred in 2.6% of insulin-glargine-treated and 2.4% of TZD-treated patients. This evidence concerns the gene GCG and Hypoglycemia.